Protein Disulfide Isomerase Disassembles TDP-43/G3BP1 Condensates and Antagonizes TDP-43 Pathological Aggregates
Jia-Qi Liu1, Hao Liu1, Yu-Xuan Sun1
1Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan, China.
Abstract:
Cytoplasmic mislocalization and aggregation of transactive response DNA-binding protein-43 (TDP-43) is a common pathological feature of amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration, and Alzheimer's disease with TDP-43 pathology (AD-TDP); the exact role of protein disulfide isomerase (PDI), an enzyme with chaperone activity, in modulating the pathological behavior of TDP-43 is unknown. In this study, we report that wild-type PDI, through its specific interaction with TDP-43, markedly attenuates phase separation of TDP-43, competitively displaces G3BP1 to disassemble TDP-43/G3BP1 condensates, and further counteracts the pathological mislocalization, abnormal phosphorylation, and pathological aggregation of TDP-43 through the b' domain of the enzyme. Ultimately, this alleviates mitochondrial damage and neuronal toxicity caused by TDP-43 aggregation and suppresses UNC13A cryptic splicing in stressed cells. In the presence of abnormal forms of PDI, however, PDI loses its activity, and stress granules containing TDP-43 are assembled into amyloid fibrils, resulting in mitochondrial impairment and neuronal cell death in ALS and AD-TDP patients. These findings not only provide new insights into the pathogenic mechanisms of TDP-43 in neurodegenerative diseases such as ALS and AD-TDP, but also propose PDI as a potential therapeutic target.
Insights
Protein disulfide isomerase (PDI) prevents toxic aggregation of transactive response DNA-binding protein-43 (TDP-43) in neurodegenerative diseases. Abnormal PDI promotes TDP-43 aggregation, leading to neuronal death, highlighting PDI as a therapeutic target.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Cytoplasmic aggregation of transactive response DNA-binding protein-43 (TDP-43) is a hallmark of neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration.
- The role of protein disulfide isomerase (PDI), a chaperone enzyme, in TDP-43 pathology remains unclear.
Purpose of the Study:
- To investigate the interaction between PDI and TDP-43.
- To determine PDI's effect on TDP-43 aggregation and its pathological consequences.
Main Methods:
- Investigated the interaction between wild-type PDI and TDP-43.
- Assessed PDI's impact on TDP-43 phase separation and condensate formation.
- Examined PDI's role in TDP-43 mislocalization, phosphorylation, and aggregation in cellular models.
Main Results:
- Wild-type PDI attenuates TDP-43 phase separation and disassembles TDP-43/G3BP1 condensates.
- PDI counteracts TDP-43 mislocalization, abnormal phosphorylation, and aggregation, alleviating mitochondrial damage and neuronal toxicity.
- Abnormal PDI loses its activity, leading to TDP-43 amyloid fibril formation, mitochondrial impairment, and neuronal cell death in ALS and AD-TDP models.
Conclusions:
- PDI plays a critical role in preventing TDP-43 aggregation and subsequent neurotoxicity.
- Dysfunctional PDI contributes to the pathogenesis of TDP-43 proteinopathies.
- PDI emerges as a potential therapeutic target for neurodegenerative diseases characterized by TDP-43 pathology.
Related Concept Videos
Protein Modifications in the RER
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal sequences.
The Unfolded Protein Response
Intrinsically Disordered Proteins
Protein Folding
Protein Structure Is Critical to Its Biological Function
Proteins perform a wide range of biological functions such as catalyzing chemical reactions, providing...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...


